Psychotherapy vs antidepressants in heart failure: Impact of adherence.

J Affect DisordJul 30, 2026 (epub)
Clinical ResearchCardiologyPsychiatry

Waguih William IsHak, Michele A Hamilton, Marcio A Diniz et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effects of behavioral activation (BA) versus antidepressant medication (MEDS) on patients with heart failure (HF) and depression, focusing on treatment adherence. Among 416 participants, those with high adherence (>75-100%) to BA showed significantly greater improvements in mental health-related quality of life (HRQoL) and HF-specific HRQoL at 6 months compared to MEDS.

Key findings

  • BA led to a 5.22 point increase in Mental HRQoL (SF-12v2-MC) compared to MEDS at 6 months.
  • BA resulted in a 16.08 point increase in HF-specific HRQoL (KCCQ-OS) compared to MEDS at 6 months.
  • No significant differences in depressive symptoms or physical HRQoL were observed at 6 months.

Why it matters

Depression is prevalent in heart failure patients, impacting their quality of life. Understanding the effectiveness of different treatment modalities can guide clinicians in optimizing care for this vulnerable population.

Source

PubMed · PMID 42532282

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.